Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 27, 2012. The report details a specific share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure and share buyback activity.
- Shares Purchased: 900,000 Ordinary shares of 25 pence each.
- Purchase Date: April 27, 2012.
- Price Range: Highest price paid was 1,429 pence per share; lowest price paid was 1,417.5 pence per share.
- Treasury Holdings (Settled): 517,042,927 shares (9.29% of total issued share capital).
- Treasury Holdings (Including Unsettled): 518,242,927 shares (10.27% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,046,599,849 shares.
Material Changes
The filing reports an increase in the Company's treasury share holdings following the purchase of 900,000 shares. Consequently, the percentage of total voting rights held in Treasury increased to 10.27% when including unsettled purchases. The filing does not provide comparative data for prior periods regarding financial performance.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,046,599,849) for calculating disclosure thresholds under FSA rules.
- Confirm the current percentage of voting rights held in Treasury (10.27% including unsettled shares).
- Review the specific price range paid (1,417.5 to 1,429 pence) for the April 27, 2012 transaction.
- Note that this filing does not contain financial performance data; refer to Form 20-F for comprehensive financial statements.